Ferumoxytol
- Generic Name
- Ferumoxytol
- Brand Names
- Feraheme
- Drug Type
- Small Molecule
- Chemical Formula
- Fe3O4
- CAS Number
- 722492-56-0
- Unique Ingredient Identifier
- G6N3J05W84
- Background
Ferumoxytol is an intravenously administered iron preparation indicated in the EU and the US for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD) .
It is comprised of superparamagnetic iron oxide nanoparticles which are coated by a semi-synthetic carbohydrate shell in an isotonic, neutral pH solution that may be administered at relatively high dose by rapid intravenous injection .
- Indication
This drug is indicated for the treatment of iron deficiency anemia in adult patients who have experienced intolerance to oral iron or have experienced an unsatisfactory response to oral iron or
who have chronic kidney disease (CKD) .
- Associated Conditions
- Iron Deficiency Anemia (IDA)
- Associated Therapies
- -
DCE MRI in Patients With Pancreatic Cancer
- Conditions
- Familial Pancreatic CancerPancreatic AdenocarcinomaPancreatic Intraductal Papillary-Mucinous Neoplasm
- Interventions
- Procedure: Dynamic Contrast-Enhanced Magnetic Resonance ImagingDrug: Ferumoxytol
- First Posted Date
- 2014-02-25
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 77
- Registration Number
- NCT02070705
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.